Largest biotechnology: biological products (no diagnostic substances) companies
Every US-listed biotechnology: biological products (no diagnostic substances) company we cover — 160 of them — ranked by market capitalisation, with revenue and earnings taken from their SEC filings.
Combined market cap
$795.719 B
0.8% of all US-listed value
Companies
160
Ranked #26 of 152 industries
Average
$4.973 B
Mean market cap per company
| # | Name | Market cap | Close | Session | Country |
|---|---|---|---|---|---|
| 1 | AmgenAMGN | $222.2B | $410.95 | +1.50% | United States |
| 2 | Gilead SciencesGILD | $165.4B | $133.21 | +1.80% | United States |
| 3 | Argenx SeARGX | $53.7B | $865.04 | -1.17% | Netherlands |
| 4 | Revolution MedicinesRVMD | $44.0B | $205.15 | +3.71% | United States |
| 5 | BiogenBIIB | $30.7B | $207.94 | +0.80% | United States |
| 6 | ModernaMRNA | $23.6B | $59.17 | +9.86% | United States |
| 7 | BioNTech SEBNTX | $23.5B | $93.67 | +2.72% | Germany |
| 8 | Neurocrine BiosciencesNBIX | $16.6B | $163.41 | +2.25% | United States |
| 9 | ExelixisEXEL | $13.4B | $54.07 | +3.58% | United States |
| 10 | Halozyme TherapeuticsHALO | $12.2B | $103.12 | +20.24% | United States |
| 11 | Bio-TechneTECH | $11.3B | $72.29 | +0.54% | United States |
| 12 | Apogee TherapeuticsAPGE | $10.2B | $134.84 | +0.26% | United States |
| 13 | Krystal BiotechKRYS | $9.66B | $326.45 | +1.17% | United States |
| 14 | RepligenRGEN | $9.25B | $163.90 | +2.80% | United States |
| 15 | Kymera TherapeuticsKYMR | $8.94B | $107.52 | +1.04% | United States |
| 16 | QiagenQGEN | $8.72B | $42.30 | +1.37% | Netherlands |
| 17 | VaxcytePCVX | $8.64B | $58.07 | -1.39% | United States |
| 18 | ImmunovantIMVT | $8.25B | $39.95 | +0.53% | United States |
| 19 | ImmunityBioIBRX | $8.10B | $7.64 | +4.37% | United States |
| 20 | Twist BioscienceTWST | $7.25B | $115.67 | +6.04% | United States |
| 21 | CG OncologyCGON | $6.62B | $75.10 | +0.33% | United States |
| 22 | Scholar RockSRRK | $6.34B | $52.92 | +0.53% | United States |
| 23 | CRISPR TherapeuticsCRSP | $5.17B | $53.52 | +3.64% | Switzerland |
| 24 | Adaptive BiotechnologiesADPT | $3.98B | $24.93 | +5.64% | United States |
| 25 | Denali TherapeuticsDNLI | $3.94B | $24.83 | +0.40% | United States |
| 26 | Relay TherapeuticsRLAY | $3.79B | $19.77 | +0.10% | United States |
| 27 | Kodiak SciencesKOD | $2.84B | $45.37 | -0.07% | United States |
| 28 | Beam TherapeuticsBEAM | $2.84B | $27.48 | +0.84% | United States |
| 29 | Iovance BiotherapeuticsIOVA | $2.83B | $6.34 | +2.09% | United States |
| 30 | Tarsus PharmaceuticalsTARS | $2.79B | $64.79 | -0.83% | United States |
| 31 | Biocryst PharmaceuticalsBCRX | $2.40B | $9.38 | +0.86% | United States |
| 32 | Hemab TherapeuticsCOAG | $2.32B | $49.66 | -4.79% | United States |
| 33 | VericelVCEL | $2.31B | $45.09 | +0.76% | United States |
| 34 | Adma BiologicsADMA | $2.22B | $9.90 | -1.59% | United States |
| 35 | MesoblastMESO | $2.06B | $15.94 | +2.05% | Australia |
| 36 | Taysha Gene TherapiesTSHA | $1.89B | $6.56 | +3.47% | United States |
| 37 | Recursion PharmaceuticalsRXRX | $1.72B | $3.22 | +1.26% | United States |
| 38 | ImmunocoreIMCR | $1.64B | $34.00 | -1.45% | United Kingdom |
| 39 | Maze TherapeuticsMAZE | $1.59B | $28.65 | +0.42% | United States |
| 40 | SL ScienceSLBT | $1.50B | $2.67 | -2.20% | Taiwan |
| 41 | Vir BiotechnologyVIR | $1.49B | $8.82 | +0.63% | United States |
| 42 | Monte Rosa TherapeuticsGLUE | $1.34B | $15.88 | +1.08% | United States |
| 43 | NovavaxNVAX | $1.31B | $7.95 | +2.71% | United States |
| 44 | Inhibrx BiosciencesINBX | $1.30B | $88.66 | +3.35% | United States |
| 45 | ImmaticsIMTX | $1.29B | $9.65 | +2.44% | Germany |
| 46 | Vor BiopharmaVOR | $1.28B | $23.67 | -0.13% | United States |
| 47 | MeiraGTxMGTX | $1.21B | $13.07 | +2.19% | United States |
| 48 | AlvotechALVO | $1.19B | $3.81 | +0.26% | Luxembourg |
| 49 | Cullinan TherapeuticsCGEM | $1.09B | $17.73 | -1.23% | United States |
| 50 | Odyssey TherapeuticsODTX | $1.02B | $21.17 | -1.76% | United States |
| 51 | Replimune GroupREPL | $1.01B | $12.06 | -6.22% | United States |
| 52 | Sana BiotechnologySANA | $979.6M | $3.52 | +3.23% | United States |
| 53 | Attovia TherapeuticsATTO | $919.3M | $20.17 | -1.03% | United States |
| 54 | Aura BiosciencesAURA | $826.5M | $7.99 | +3.50% | United States |
| 55 | Solid BiosciencesSLDB | $826.0M | $8.39 | -3.67% | United States |
| 56 | DBV TechnologiesDBVT | $798.2M | $13.48 | -1.89% | France |
| 57 | Candel TherapeuticsCADL | $775.9M | $10.59 | +0.10% | United States |
| 58 | Agomab TherapeuticsAGMB | $714.1M | $14.50 | +7.41% | Belgium |
| 59 | Allogene TherapeuticsALLO | $693.8M | $2.01 | +2.03% | United States |
| 60 | Tectonic TherapeuticTECX | $584.6M | $30.98 | +2.52% | United States |
| 61 | Zura BioZURA | $566.7M | $5.97 | +4.47% | Cayman Islands |
| 62 | 4D Molecular TherapeuticsFDMT | $562.0M | $10.75 | +1.90% | United States |
| 63 | Autolus TherapeuticsAUTL | $561.6M | $2.11 | +5.50% | United Kingdom |
| 64 | Prime MedicinePRME | $556.3M | $3.08 | +4.41% | United States |
| 65 | RegenxbioRGNX | $554.2M | $10.72 | -4.96% | United States |
| 66 | Artiva BiotherapeuticsARTV | $550.9M | $11.27 | -2.68% | United States |
| 67 | Eikon TherapeuticsEIKN | $502.9M | $9.29 | +0.87% | United States |
| 68 | Valneva SEVALN | $502.9M | $5.30 | +2.32% | France |
| 69 | ProkidneyPROK | $495.4M | $1.64 | +0.00% | United States |
| 70 | Ginkgo BioworksDNA | $495.2M | $7.97 | -6.24% | United States |
| 71 | Kyverna TherapeuticsKYTX | $483.9M | $7.96 | +2.71% | United States |
| 72 | Cabaletta BioCABA | $454.9M | $2.79 | +1.09% | United States |
| 73 | Editas MedicineEDIT | $442.3M | $2.88 | -0.69% | United States |
| 74 | X4 PharmaceuticalsXFOR | $437.6M | $4.64 | +11.27% | United States |
| 75 | OcugenOCGN | $434.1M | $1.28 | +3.23% | United States |
| 76 | Scribe TherapeuticsSCTX | $420.7M | $26.00 | +2.32% | United States |
| 77 | Sutro BiopharmaSTRO | $420.6M | $25.38 | +5.09% | United States |
| 78 | C4 TherapeuticsCCCC | $412.4M | $3.73 | +2.47% | United States |
| 79 | Fennec PharmaceuticalsFENC | $403.8M | $11.58 | +6.78% | United States |
| 80 | Compass TherapeuticsCMPX | $387.2M | $2.15 | +8.04% | United States |
| 81 | Lexeo TherapeuticsLXEO | $377.7M | $4.81 | +5.71% | United States |
| 82 | Palisade BioPALI | $366.3M | $2.11 | +0.96% | United States |
| 83 | Century TherapeuticsIPSC | $360.7M | $2.00 | +5.26% | United States |
| 84 | Fate TherapeuticsFATE | $326.4M | $2.80 | +12.45% | United States |
| 85 | Inhibikase TherapeuticsIKT | $326.1M | $2.47 | +2.49% | United States |
| 86 | AgenusAGEN | $311.5M | $6.96 | -7.08% | United States |
| 87 | Anavex Life SciencesAVXL | $309.5M | $3.34 | +1.83% | United States |
| 88 | Neumora TherapeuticsNMRA | $302.0M | $1.63 | -0.61% | United States |
| 89 | SAB BiotherapeuticsSABS | $298.2M | $3.90 | +1.30% | United States |
| 90 | SurrozenSRZN | $297.5M | $25.62 | +18.39% | United States |
| 91 | Lineage Cell TherapeuticsLCTX | $274.2M | $1.10 | -2.65% | United States |
| 92 | Protara TherapeuticsTARA | $231.6M | $4.12 | +0.49% | United States |
| 93 | CompugenCGEN | $227.9M | $2.41 | +4.78% | Israel |
| 94 | InvivydIVVD | $218.0M | $0.74 | +12.29% | United States |
| 95 | Protalix BioTherapeuticsPLX | $198.2M | $2.46 | +0.82% | Israel |
| 96 | AlectorALEC | $197.6M | $1.78 | -2.73% | United States |
| 97 | Voyager TherapeuticsVYGR | $197.6M | $3.27 | +4.47% | United States |
| 98 | Coherus OncologyCHRS | $196.2M | $1.27 | +0.40% | United States |
| 99 | Precision BiosciencesDTIL | $193.3M | $7.49 | +0.94% | United States |
| 100 | Outlook TherapeuticsOTLK | $190.7M | $1.02 | +4.88% | United States |
Showing the largest 100 of 160 companies. One row per company — secondary share classes are folded into their primary listing. Updated 9 Aug 2026.
Sectors biotechnology: biological products (no diagnostic substances) companies sit in
Other industries
Semiconductors 100Computer Software: Programming Data Processing 77Computer Software: Prepackaged Software 232Computer Manufacturing 10Biotechnology: Pharmaceutical Preparations 501Major Banks 245Industrial Machinery/Components 209Catalog/Specialty Distribution 30Business Services 93Commercial Banks 35Auto Manufacturing 29Integrated oil Companies 18Investment Bankers/Brokers/Service 68Real Estate Investment Trusts 179Department/Specialty Retail Stores 14Oil & Gas Production 116Telecommunications Equipment 82Beverages (Production/Distribution) 35Electronic Components 21Finance: Consumer Services 163Electric Utilities: Central 59Consumer Electronics/Appliances 23Natural Gas Distribution 29Medical Specialities 44All industries →
Figures come from SEC filings and daily market prices. Companies listed only outside the US are not covered — see methodology.